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ABSTRACT 
A new series of 4-chloro-N-(2-(substitutedphenyl)-4-oxothiazolidin-3-yl)-2-phenoxybenzamide derivatives were 
designed, synthesized and biologically evaluated as anticonvulsant agents. The designed compounds have the main 
essential functional groups for binding to the benzodiazepine receptors and 4-thiazolidinone ring as an anticonvul-
sant pharmacophore. Some of the new synthesized compounds showed considerable anticonvulsant activity in 
electroshock and pentylenetetrazole-induced lethal convulsion tests. Compound 5i, 4-chloro-N-(2-(4-methoxy-
phenyl)-4-oxothiazolidin-3-yl)-2-phenoxybenzamide, with the best activity was selected for evaluation of other 
benzodiazepine pharmacological effects. This compound induced significant sedative-hypnotic activity. However, 
it does not impair the learning and memory in the experimental condition. Flumazenil was able to antagonize the 
sedative-hypnotic and anticonvulsant effects of compound 5i indicating that benzodiazepine receptors are highly 
involved in the pharmacological properties of the novel compounds. 
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INTRODUCTION 
Finding of novel anticonvulsant agents 
and new ligands for the benzodiazepine 
(BZD) binding site of the GABA receptor has 
been an interesting field of drug design in the 
recent decade. These compounds have im-
portant pharmacological effects for the treat-
ment of numerous central nervous system 
(CNS) disorders such as anxiety, insomnia 
and epilepsy (Smith et al., 1995; Rudolph and 
Knoflach, 2011). However, BZD’s usefulness 
is limited by a broad range of unwanted side 
effects; including sedation, amnesia, ataxia 
and risk of drug dependence (Alerno et. al., 
2012). Therefore, it is important to synthesize 
novel ligands of the BZD receptor with an-
tiepileptic activity and less undesirable ef-
fects. 
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Classical BZDs are considered as positive 
allosteric modulators by binding to a distinct 
site on the GABAA receptors (Guerrini et. al., 
2006), which are the greatest population of 
brain inhibitory neurotransmitter receptors 
(Guerrini et. al., 2007). The GABAA receptors 
are symmetric heteropentamers that are made 
of different subunits “(α1–6, β1–3, γ1–3, δ, ε, 
θ, π and ρ1–3) with an integral channel that is 
permeable to chloride ions” (Rudolph and 
Knoflach, 2011). Most of the GABAA recep-
tors are made of α, β and γ subunits, and are 
arranged around the selective chloride ion 
gate with the stoichiometry of 2 α subunits, 2 
β subunits and 1 γ subunit. The binding site of 
BZDs is located between α and γ subunits 
(Rudolph and Knoflach, 2011; Alerno et. al., 
2012; Grunwald et al., 2006). 
There are several pharmacophore models 
proposed for the binding of ligands to benzo-
diazepine receptors. Two of these models are 
more commonly seen in high affinity benzo-
diazepine ligands. The first one is an aromatic 
ring with a suitable distance (5Å) from a pro-
ton accepting functional group located in the 
same plane and the second one is presence of 
the aromatic ring located in a plane perpen-
dicular to the plane of the first aromatic ring 
(Akbarzadeh et al., 2003). Furthermore, the 
previously reported article revealed that thia-
zolidinone derivatives exhibit anticonvulsant 
activity (Tripathi et al., 2014). Based on these 
evidences and our earlier published papers on 
flexible novel heterocyclic compounds (Ak-
barzadeh et al., 2003; Almasirad et al., 2004; 
Zarghi et al., 2005; Almasirad et al., 2007; 
Zarghi et al., 2008a; Mahdavi et al., 2010; 
Faizi et al., 2012; Tabatabai et al., 2013; 
Zarghi et al., 2008a, b; Faizi, et al., 2015) , 
some new thiazolidinone derivatives that 
have the essential pharmacophore groups for 
binding to the BZD’s receptors were devel-
oped (Figure 1). Design of the novel com-
pounds was based on hybridation between 4-
thiazolidinone and 2-phenoxyphenyl pharma-
cophores. Since both pharmacophores have 
shown anticonvulsant activity, it is expected 
that the final structures demonstrate compre-
hensive anticonvulsant effects. Further, the 
BBB permeably and physicochemical proper-
ties of compounds for prediction of oral bioa-
vailability were evaluated. In order to deter-
mine the anticonvulsant effects of synthesized 
compounds, the penthylentetrazole (PTZ)-in-
duced lethal convulsion and maximal electro-
shock (MES) tests were performed and the re-
sults were compared with diazepam, a well-
known BZD agonist. The most potent com-
pound was selected to evaluate its effect on 
learning and memory and the hypnotic activ-
ity by passive avoidance test and potentiating 
of the pentobarbital sleeping time model re-
spectively. Also, the neurotoxicity of this 
compound was evaluated by the rotarod test 
and the involvement of BZD receptor in the 
effects of the novel compounds was con-
firmed by using flumazenil as an antagonist of 
BZD receptor. 
 
 
Figure 1: The structure of the novel compounds 
consist of A: an aromatic ring, B: a coplanar pro-
ton accepting group and C: a second out-of-plane 
aromatic ring, D: adjunct thiazolidinone pharma-
cophore 
 
MATERIALS AND METHODS 
Chemistry 
Melting points were taken on an Electro-
thermal 9300 apparatus (Ontario, Canada) 
and are uncorrected. Infrared spectra and ele-
mental analysis were obtained using Shi-
madzu FT-IR 8400S spectrographs (KBr 
disks) and elemental analyser (Costech, Italy) 
respectively. 1H-NMR spectra was recorded 
on a Bruker FT-500 MHz instrument (Bruker 
Biosciences, USA) using chloroform-d as sol-
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vents. Mass were obtained using a 5973 net-
work mass selective detector at 70 eV (Ag-
ilent Technology). All chemicals and reagents 
were obtained commercially from Sigma/Al-
drich or Merck Company and were used with-
out further purification. All of the intermedi-
ates were synthesized according to our previ-
ously reported articles (Akbarzadeh et al., 
2003; Almasirad et al., 2006). 
General Procedures for the Synthesis of 5a-
5j 
A mixture of hydrazide 4 (3.80 mmol) and 
corresponding aldehyde (3.80 mmol) in abso-
lute ethanol was stirred at room temperature 
for 2 to 20 hours in the presence of hydrochlo-
ric acid (2 drops) as a catalyst. After the end 
of the reaction the mixture was concentrated, 
neutralized by a 10 % aqueous (aq) solution 
of sodium bicarbonate and the resulting hy-
drazone was washed with water, dried and 
used in the next step without further purifica-
tion. To a suspension of corresponding hydra-
zone (2.8 mmol) and Thioglycolic acid (0.38 
ml, 5.60 mmol) in dry toluene, catalytic 
amounts of anhydrous ZnCl2 was added and 
the mixture was refluxed in a round-bottomed 
flask equipped with a Dean-Stark apparatus 
for 20 hours. After this time, the solvent was 
evaporated and NaHCO3 10 % (aq) was 
added. Finally the precipitate was filtered and 
recrystallized from ethyl acetate. 
4-Chloro-N-(4-oxo-2-phenylthiazolidin-3-
yl)-2-phenoxybenzamide (5a) 
Yield 64 %; m. p. 102-104° C; FT-IR (KBr) 
(, cm-1): 3311 (NH), 1726 (C=O), 1652 
(C=O); 1H-NMR (CDCl3, 500MHz): ppm 
9.05 (s, 1H, NH), 8.14 (d, J = 10.5 Hz, 1H, 
aromatic), 7.38-7.27 (m, 4H, aromatic), 7.24-
7.21 (m, 4H, aromatic), 7.14 (dd, J = 8.5, 2.0 
Hz, 1H, aromatic), 6.76 (dd, J = 9.0, 3.5 Hz, 
2H, aromatic), 6.64 (d, J = 2.0 Hz, 1H, aro-
matic), 6.03 (s, 1H, Ar-CH) , 3.92, 3.75 (2d, J 
= 14.5 Hz, 2H, SCH2); MS: m/z (%) 426 
(M++2,11), 424 (M+,33), 247(35), 233(80), 
231(100), 196(43), 168(62), 155(37), 
139(67), 121(29), 93(90), 77(64). Anal. Calcd 
for C22H17ClN2O3S: C, 62.19; H, 4.03; N, 
6.59. Found: C, 62.40; H, 3.96; N, 6.45. 
4-Chloro-N-(2-(4-hydroxyphenyl)-4-oxothia-
zolidin-3-yl)-2-phenoxybenzamide (5b) 
Yield 50 %; m. p. 126-128° C; IR (KBr) (, 
cm-1): 3320, (OH, NH), 1728 (C=O), 1661 
(C=O); 1H NMR (CDCl3, 500MHz): ppm 
9.00 (s,1H, NH), 8.14 (d, J = 8.5 Hz, 1H, aro-
matic), 7.37 (m, 2H, aromatic), 7.30-7.16 (m, 
3H, aromatic), 7.14 (dd, J = 8.5,2.0 Hz, 1H, 
aromatic), 6.78 (d, J = 7.5 Hz, 2H, aromatic), 
6.75 (d, J = 7.8 Hz, 2H, aromatic) 6.74 (d, J = 
2.0 Hz, 1H, aromatic), 6.02 (s, 1H, Ar-CH), 
3.90, 3.73 (2d, J = 16.0 Hz, 2H, SCH2), 3.71 
(s, 1H, OH); MS: m/z (%) 442 (M++2, 6), 440 
(M+,18), 33 (100), 231 (33), 208 (22), 168 
(28), 155 (27), 139 (40), 111 (32), 97 (55), 84 
(71), 69 (91), 57 (99). Anal. Calcd for 
C22H17ClN2O4S: C, 59.93; H, 3.89; N, 6.35. 
Found: C, 59.71; H, 3.93; N, 6.41. 
N-(2-(3,5-Di-tert-butyl-4-hydroxyphenyl)-4-
oxothiazolidin-3-yl)-4-chloro-2 phenoxyben-
zamide (5c) 
Yield 50 %; m. p. 188-200° C; IR (KBr) (, 
cm-1): 3502, (OH, bonded), 3370 (OH, non-
bonded and NH), 1732 (C=O), 1658 (C=O); 
1H-NMR (CDCl3, 500MHz): ppm 8.99 (s, 
1H, NH), 8.19 (d, J = 8.5 Hz, 1H, aromatic), 
7.36 (t, 2H, aromatic), 7.24 (t, 1H, aromatic), 
7.17 (s, 2H, aromatic), 7.13 (dd, J = 8.5, 2.0 
Hz, 1H, aromatic), 6.78 (d, J = 8.0 Hz, 2H, 
aromatic), 6.58 (d, J = 2.0 Hz, 1H, aromatic), 
5.99 (s, 1H, Ar-CH), 5.28 (s, 1H, OH), 3.90, 
3.70 (2d, J = 16.0 Hz, 2H, SCH2), 1.28 (s, 
18H, CH3); MS: m/z (%) 554 (M++2,4), 552 
(M+,12), 306 (100), 290 (62), 263 (24), 248 
(87), 233 (77), 231 (99), 216 (16), 196 (20), 
168 (28), 139 (31), 93 (27), 77 (16), 57 (64). 
Anal. Calcd for C30H33ClN2O4S: C, 65.14; H, 
6.01; N, 5.06. Found: C, 65.50; H, 5.96; N, 
5.00. 
4-Chloro-N-(2-(4-(dimethylamino)phenyl)-4-
oxothiazolidin-3-yl)-2-phenoxybenzamide 
(5d) 
Yield 50 %; m. p. 152-153° C; IR (KBr) (, 
cm-1): 3381 (NH), 1717 (C=O), 1667 (C=O); 
1H-NMR (CDCl3, 500MHz): ppm 9.01 (s, 
1H, NH), 8.14 (d, J = 8.5 Hz, 1H, aromatic), 
7.32 (m, 2H, aromatic), 7.24-7.14 (m, 3H, ar-
omatic), 7.12 (dd, J = 8.5, 2.0 Hz, 1H, aro-
matic), 6.77 (dd, J = 6.5, 2.0 Hz, 2H, aro-
matic), 6.61(d, J = 1.5 Hz, 1H, aromatic) 6.49 
(d, J = 6.5Hz, 2H, aromatic), 5.97 (s, 1H, Ar-
CH), 3.92, 3.71 (2d, J = 16.0 Hz, 2H, SCH2), 
2.89 (s, 6H, CH3); MS: m/z (%) 469 (M++2, 
3), 467 (M+, 9), 336 (16), 233 (100), 231 (99), 
196 (32), 168 (54), 147 (79), 134 (28), 93 
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(38), 77 (41), 57 (34). Anal. Calcd for 
C24H22ClN3O3S: C, 61.60; H, 4.74; N, 8.98. 
Found: C, 61.25; H, 4.80; N, 8.93. 
N-(2-(2-bromophenyl)-4-oxothiazolidin-3-
yl)-4-chloro-2-phenoxybenzamide (5e) 
Yield 50 %; m. p. 125-127° C; IR (KBr) (, 
cm-1): 3555 (NH), 1731 (C=O), 1672 (C=O); 
1H-NMR (CDCl3, 500MHz): ppm 9.14 (s, 
1H, NH), 8.15 (d, J = 8.5 Hz, 1H, aromatic), 
7.44(d, J = 7.5 Hz, 1H, aromatic), 7.42-7.20 
(m, 4H, aromatic), 7.19-7.02 (m, 3H, aro-
matic), 6.87 (d, J = 8.5 Hz, 2H, aromatic), 
6.68 (d, J = 2.0 Hz, 1H, aromatic) 6.47 (s, 1H, 
Ar-CH), 3.89, 3.75 (2d, J = 16.0 Hz, 2H, 
SCH2); MS: m/z (%) 506 (M++4, 7), 
504(M++2, 28), 502(M+, 21), 233 (38), 231 
(100), 168 (19), 139 (28), 121 (16), 93 (33), 
77 (21), 57 (18). Anal. Calcd for 
C22H16BrClN2O3S: C, 52.45; H, 3.20; N, 5.56. 
Found: C, 52.61; H, 3.16; N, 5.52. 
4-Chloro-N-(2-(4-chlorophenyl)-4-oxothia-
zolidin-3-yl)-2-phenoxybenzamide (5f) 
Yield 50 %; m. p. 113-115° C; IR (KBr) (, 
cm-1): 3284 (NH), 1722 (C=O), 1672 (C=O); 
1H-NMR (CDCl3, 500MHz): ppm 9.03 (s, 
1H, NH), 8.13 (d, J = 8.5Hz, 1H, aromatic), 
7.41-7.15(m, 8H, aromatic), 6.77 (d, J = 8.0 
Hz, 2H, aromatic), 6.68 (d, J = 2.0 Hz, 1H, 
aromatic), 6.01 (s, 1H, Ar-CH), 3.91, 3.73 
(2d, J = 16.0 Hz, 2H, SCH2); MS: m/z (%) 
462 (M++4,4), 460 (M++2, 24), 458 (M+,36), 
247 (44), 233 (88), 231 (100), 212 (61), 196 
(24), 168 (33), 155 (30), 139 (51), 93 (99), 77 
(31). Anal. Calcd for C22H16Cl2N2O3S: C, 
57.52; H, 3.51; N, 6.10. Found: C, 57.61; H, 
3.43; N, 5.91. 
4-Chloro-N-(2-(3-nitrophenyl)-4-oxothiazol-
idin-3-yl)-2-phenoxybenzamide (5g) 
Yield 50 %; m. p. 99-100° C; IR (KBr) (, 
cm-1): 3321 (NH), 1726 (C=O), 1665 (C=O), 
1531, 1352 (NO2); 1H-NMR (CDCl3, 
500MHz): ppm 9.12 (s, 1H, NH), 8.21 (s, 
1H, aromatic), 8.08(d, J = 8.5Hz , 1H, aro-
matic), 8.01 (d, J = 8.5 Hz, 1H, aromatic), 
7.72 (d, J = 8.5 Hz, 1H, aromatic), 7.40-7.21 
(m, 4H, aromatic), 7.15 (d, J = 7.5 Hz, 1H, 
aromatic), 6.73 (d, J = 7.5 Hz, 2H, aromatic), 
6.74 (s, 1H, aromatic), 6.11 (s, 1H, Ar-CH), 
3.91, 3.80 (2d, J = 16.0 Hz, 2H, SCH2). MS: 
m/z (%) 471 (M++2, 5), 469 (M+, 15), 247 
(15), 233 (71), 231 (100), 196 (17), 168 (38), 
139 (32), 93 (87), 70 (70). Anal. Calcd for 
C22H16Cl1N3O5S: C, 56.23; H, 3.43; N, 8.94. 
Found: C, 57.17; H, 3.23; N, 8.85. 
4-Chloro-N-(2-(4-nitrophenyl)-4-oxothiazol-
idin-3-yl)-2-phenoxybenzamide (5h) 
Yield 50 %; m. p. 168-170° C; IR (KBr) (, 
cm-1): 3398 (NH), 1731 (C=O), 1679 (C=O), 
1528,1349 (NO2); 1H-NMR (CDCl3, 
500MHz): ppm 9.04 (s,1H, NH), 8.11(d, J = 
9.0 Hz , 1H, aromatic), 8.03 (d, J = 8.5 Hz, 
2H, aromatic), 7.52 (d, J = 8.5 Hz, 2H, aro-
matic), 7.32-7.29 (t, 2H, aromatic), 7.22-7.17 
(m, 2H, aromatic), 6.72 (d, J = 8.0 Hz, 2H, 
aromatic), 6.69 (d, J = 2.0 Hz, 1H, aromatic), 
6.11 (s, 1H, Ar-CH), 3.92, 3.75 (2d, J = 16.0 
Hz, 2H, SCH2); MS: m/z (%) 471 (M++2, 5), 
469 (M+, 15), 368 (9), 247 (18), 233 (73), 231 
(100), 196 (16), 168 (31), 139 (38), 93 (87), 
70 (72). Anal. Calcd for C22H16Cl1N3O5S: C, 
56.23; H, 3.43; N, 8.94. Found: C, 55.98; H, 
3.50; N, 8.92. 
4-Chloro-N-(2-(4-methoxyphenyl)-4-oxothia-
zolidin-3-yl)-2-phenoxybenzamide (5i) 
Yield 50 %; m. p 121-123° C; IR (KBr) (, 
cm-1): 3319 (NH), 1722 (C=O), 1659 (C=O); 
1H-NMR (CDCl3, 500MHz): ppm 9.01 (s, 
1H, NH), 8.13 (d, J = 9.0 Hz, 1H, aromatic), 
7.38-7.24 (m, 6H, aromatic), 7.14 (d, J = 8.5 
Hz, 1H, aromatic), 6.77 (d, J = 7.5 Hz, 2H, 
aromatic), 6.72 (d, J = 8.5 Hz, 2H, aromatic), 
6.64 (s, 1H, aromatic), 5.99 (s, 1H, Ar-CH), 
3.91 , 3.68 (2d, J = 16.0 Hz, 2H, SCH2), 3.66 
(s, 3H, CH3); MS: m/z (%) 457 (M++2,2), 455 
(M+,6), 233 (51), 231 (100), 208 (96), 196 
(21), 168 (33), 151 (28), 134 (60), 93 (55), 77 
(78). Anal. Calcd for C23H19Cl1N2O4S: C, 
60.72; H, 4.21; N, 6.16. Found: C, 60.82; H, 
4.16; N, 6.09. 
4-Chloro-N-(4-oxo-2-p-tolylthiazolidin-3-
yl)-2-phenoxybenzamide (5j) 
Yield 50 %; m.p. 133-135° C; IR (KBr) (, 
cm-1): 3326 (NH), 1731 (C=O), 1659 (C=O); 
1H-NMR (CDCl3, 500MHz): ppm 10.48 
(s,1H, NH), 7.43 (d, J = 8.3 Hz, 1H, aro-
matic), 7.38 (t, 2H, aromatic), 7.28-7.18 (m, 
4H, aromatic), 7.03 (d, J = 7.8 Hz, 2H, aro-
matic), 6.90 (d, J = 7.7 Hz, 2H, aromatic), 
6.77 (d, J = 1.7 Hz, 1H, aromatic), 5.81 (s, 1H, 
Ar-CH), 3.87, 3.76 (d, J = 15.8 Hz, 2H, 
SCH2), 2.20 (s, 3H, CH3); MS: m/z (%) 440 
(M++2, 9), 438 (M+, 27), 247 (35), 233 (78), 
231 (100), 192 (59), 168 (56), 155 (33), 139 
(62), 118 (34), 93 (82), 77 (38), 57 (15). Anal. 
Calcd for C23H19Cl1N2O3S: C, 62.94; H, 4.36; 
N, 6.38. Found: C, 63.15; H, 4.38; N, 6.29. 
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Pharmacology 
Animals and drugs 
For pharmacological tests, we used male 
NMRI albino mice (weighing 18-22 g; 12 
weeks old) obtained from Pasteur Institute 
(Iran). All animals were kept in the animal 
house of School of Pharmacy for 7 days in or-
der to adapt to the new place. The mice were 
kept in standard cages in a typical room in the 
animal house with controlled conditions de-
signed for experimental animals and have un-
restricted access to water and food. Before 
starting the experiments, mice were also 
transferred to the testing rooms 60 minutes 
before the tests to get acclimatized to the ex-
perimental condition. We randomly divided 
the mice into experimental groups and all 
mice were used only once in the experiments. 
Ethical Committee of Shahid Beheshti Uni-
versity of Medical Sciences approved all the 
protocols of the experiments before starting 
the study. All the tests on animals were done 
based on NIH publication #85-23. In all pro-
tocols we used the least possible number of 
animals and all ethical advises for work on ex-
perimental animals were considered. In this 
study, diazepam was used as a standard ben-
zodiazepine, and flumazenil was used as an-
tagonist of benzodiazepine receptors. A mix-
ture of DMSO and water (1:10) was used as 
the solvent for the novel compounds, diaze-
pam, and flumazenil were injected 5 ml/kg 
i.p.; 30 minutes before the experiments. PTZ, 
pentobarbital, and midazolam were dissolved 
in distilled water and injected i.p. (volume of 
injection was 5 ml/kg).  
The anticonvulsant activity  
Two experimental models including PTZ 
and MES induced convulsions were used to 
test the anticonvulsant effects of the novel 
compounds. In PTZ test, different doses of the 
novel compounds or diazepam were injected 
and after 30 min, lethal dose of PTZ (100 
mg/kg) were injected. We recorded the num-
ber of mice protected from PTZ induced con-
vulsion and death for data analysis. In MES 
model, different doses of the novel com-
pounds or diazepam were injected and after 
30 minutes, MES were applied (60 Hz, 37.2 
mA and 0.25 s) using ear electrodes. We rec-
orded the number of mice protected from hind 
limb tonic extension (HLTE) induced by 
MES for data analysis (Zarghi et al., 2005, 
2008a). 
Potentiation of pentobarbital sleeping time 
For the evaluation of hypnotic effects of 
the novel compounds and diazepam, we in-
jected different doses of the novel compounds 
and diazepam (1 mg/kg) and after 30 minutes, 
injected pentobarbital (65 mg/ kg i.p.) We 
recorded the duration of loss of righting re-
flex, which represents the sleeping time. 
Since pentobarbital may cause hypothermia, 
animals were located on the top of an electric 
blanket (set at 37° C) after administration of 
pentobarbital (Faizi et al., 2015). 
Passive avoidance test 
In order to assess the effect of the novel 
compounds and midazolam on anterograde 
memory, previously described step-through 
passive avoidance test was used. Mice were 
placed into two compartment, light and dark, 
apparatus. On the first day (training day) the 
novel compounds or midazolam were injected 
and 30 minutes later each animal was located 
inside the light comportment and let it to 
freely move. Thirty seconds later the door be-
tween two compartments was opened and 
mouse was able to easily pass the door. Im-
mediately after entering to the dark compart-
ment, an unpleasant electrical shock (0.5 mA, 
2 seconds) was delivered to the mouse from 
bottom of the compartment. On the second 
day (testing day), animal was located in the 
light compartment and the delay time for each 
mouse to enter the dark compartment was rec-
orded (Faizi et al., 2015). 
Neurotoxicity evaluation 
The neurotoxicity of the compound 5i was 
measured in mice by the rotarod test. The 
mice were trained to stay on a rotarod of di-
ameter 1 inch that rotates at 6 rpm and were 
given i.p. of the 5i. If in each trial mouse was 
not able to stay at least 1 minute on the 
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rotarod, it was considered as neurotoxicity-in-
duced deficit in coordination or balance (Sałat 
et al., 2013). 
Data analysis 
ED50 of the anticonvulsant effects of the 
all tested compounds were calculated by pro-
bit-regression analysis using SPSS software 
(Chicago, IL; 1 version 13). To compare the 
ED50s, Fisher’s exact probability test was 
used. Results of PTZ and MES experiments 
were reported as mean with 95 % confidence 
intervals. Results of the other experiments 
were reported as mean ± SEM and one-way 
analysis of variance (ANOVA) with Tukey’s 
HSD post hoc test were used to analyse the 
results. In all tests, if P-value was less than 
0.05, we concluded that a significant differ-
ence existed. 
 
RESULTS AND DISCUSSION 
Prediction of the BBB permeably of  
compounds 
Anticonvulsant agents similar to other 
CNS active compounds should be able to pass 
through blood-brain barrier (BBB). So the in 
silico prediction of the BBB permeably of the 
designed compounds was done by the BBB 
prediction server which is a part of AlzPlat-
form (Liu et al., 2014), using support vector 
machine (SVM_Molptint 2D) algorithm 
(http://www.cbligand.org/BBB). The ability 
or inability of a compound to penetrate blood-
brain barrier (BBB+/BBB-) depends on the 
BBB score in the selected algorithm. When it 
is more than zero, compound could be con-
sider as BBB+ and the best score is in the 
range of 0.2-0.4. The scores of the designed 
compounds were in the range of 0.139-0.681, 
so it was deduced that all of the novel com-
pounds are BBB+ and the density of com-
pounds 5a, 5d-5f, 5i-5j in the CNS could be 
more than other compounds. 
 
Physicochemical properties 
The physicochemical properties and the 
Lipinski’s rule of five parameters for predic-
tion of oral bioavailability were determined 
by molinspiration online program (www. 
molinspiration.com) and also the clogp was 
achieved by Osiris Property Explorer (OPE) 
(http://www.organic-chemistry.org/prog/peo/) 
(Table 1) (Lipinski et al., 2012). According to 
the Lipinski’s rule for oral absorption of com-
pounds, their molecular weight should be 
lower than 500, the number of hydrogen bond 
donor and acceptor should be ≤ 5 and ≤ 10 re-
spectively, the topological polar surface area 
should be ≤ 140 and number of rotatable 
bonds ≤ 10 and two violations of this rule will 
result to the poor oral absorption. As shown 
in Table 1, all compounds except compound 
5c can be absorbed orally (Table 1).  
 
Chemistry 
The designed compounds were synthe-
sized according to the Figure 2, 4-Chloro-2-
phenoxybenzoic acid 1 was synthesized 
through a nucleophilic aromatic substitution 
reaction of 2,4-dichlorobenzoic acid and phe-
nol. Following esterification of 1, 4-chloro-2-
phenoxybenzohydrazide 3, was prepared in 
satisfactory yield by the reaction of ester 2 
with hydrazine hydrate at room temperature 
(Rezaee et al., 2014a, b). Treatment of hydra-
zide 3 with corresponding benzaldehyde fol-
lowed by reaction with thioglycolic acid af-
forded final products (5a-5j) (Shingalapur et 
al., 2010; Almasirad et al., 2006). The final 
compounds were characterized through 1H-
NMR, FT-IR, Mass spectra and elemental 
analysis. 
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5a, R=H, 5b, R=4-OH, 5c, R=4-OH, 3,5=tbutyl
5d, R=4-N(CH3)2, 5e, R=2-Br, 5f , R=4-Cl
5g, R=3-NO2, 5h, R=4-NO2, 5i, R=4-OCH3
5j, R=4-CH3  
Figure 2: Synthesis of the novel thiazolidinone compounds 5a-5j. (a) phenol, NaH 60 %, Cu, Dry DMF, 
reflux, 20h, 61 %; (b) H2SO4, MeOH, reflux, 24h, 87 %; (c) NH2NH2.H2O, EtOH, rt, 24h, 93 %; (d) 1) 
appropriate benzaldehyde, HCl 37 %, absolute EtOH, rt, 2-20h 2) thioglycolic acid, ZnCl2, dry toluene, 
reflux, 20 h, 50-64 % 
 
 
Table 1: Pharmacokinetic parameters important for good oral bioavailability of the synthesized com-
pounds 5a-5j 
Compound MW Clogpa TPSAb HBDc HBAd NROTBe LVf 
5a 425 3.33 58.64 1 5 5 0 
5b 441 2.99 78.87 2 6 5 0 
5c 553 6.15 78.87 2 6 7 2 
5d 468 3.23 61.88 1 6 6 0 
5e 504 4.05 58.64 1 5 5 1 
5f 459 3.94 58.64 1 5 5 0 
5g 470 2.41 104.47 1 8 6 0 
5h 470 2.41 104.47 1 8 6 0 
5i 455 3.26 67.88 1 6 6 0 
5j 439 3.68 58.64 1 5 5 0 
a CLog P: logarithm of partition coefficient of compound between n-octanol and water 
b Topological polar surface area. 
c Number of hydrogen bond donors 
d Number of hydrogen bond acceptors 
e Number of rotatable bonds 
f Lipinski’s Violation 
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Table 2: ED50 of the novel thiazolidinone compounds and diazepam in PTZ and MES tests in mice 
ED50 mg/kga R Compound 
MES PTZ 
11.81 (7.62-19.18)b>100 H 5a 
33.22 (23/09-49.65)b>100 4-OH 5b 
>100 >100 4-OH,3,5-di-t-Bu5c 
>100 >100 4-N(CH3)2 5d 
6.49 (4.62-9.08)b>100 2-Br 5e 
57.61 (40.46-75.74)b>100 4-Cl 5f 
>100 >100 3-NO2 5g 
20.00 (12.99-30.79)b>100 4-NO2 5h 
3.54(2.40- 5.20)b18.98 (15.41 - 23.06)b4-OCH3 5i 
>100 >100 4-CH3 5j 
1.02 (0.73-1.26)b 0.96 (0.66-1.20)b - Diazepam 
a n=10, 95 % confidence intervals in parenthesis. 
b ED50 was significantly increased in the presence of flumazenil 10 mg/kg (p < 0.05). 
 
 
Pharmacology 
The anticonvulsant activity 
PTZ induced lethal convulsion test and 
MES test were used for evaluation of anticon-
vulsant effects of the compounds. Results 
shown in Table 2 indicate that, compounds 
5a, 5b, 5c, 5d, 5e, 5f, 5g, 5h and 5j were in-
active in PTZ model. Compound 5i was the 
only compound, which showed significant an-
ticonvulsant effect in PTZ model. Com-
pounds 5c, 5d, 5g and 5j had no significant 
anticonvulsant effect in the MES model but 
other compounds, including 5i, showed sig-
nificant activity in this model. According to 
the lower ED50, it could be concluded that 5i 
was the most potent compound between the 
novel thiazolidinone derivatives in the two 
models. In both MES and PTZ tests, fluma-
zenil was able to significantly reduce the ef-
fect of the compounds with anticonvulsant ac-
tivity. 
Potentiation of pentobarbital sleeping time 
Hypnotic effect of compound 5i was eval-
uated by increasing pentobarbital sleeping 
time. According to Figure 3, the sleeping time 
was increased by the injection of compound 
5i and the effect was dose-dependent. How-
ever, the pharmacological effects of com-
pound 5i were blocked after injection of 
flumazenil, which indicates that BZD recep-
tors are responsible for these effects. 
Passive avoidance test 
The passive avoidance test was used to 
evaluate the effects of compound 5i on ante-
rograde memory. As shown in Figure 4, com-
pound 5i in doses of 3.5 and 7 mg/kg had no 
destructive effect on anterograde memory 
comparing to the control group, but in dose of 
14 mg/kg the anterograde amnesia was in-
duced by this compound.  
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Figure 3: Effect of compound 5i on potentiation of 
pentobarbital sleeping time: the time period of loss 
of righting reflex, which is conidered as sleeping 
time is presented. Results are shown as 
mean±SEM. In all groups n=10. ns represents not 
significant, * represents p<0.05, ** represents 
p<0.01, and *** represents p<0.001 compared to 
the control group. ### represents p<0.001com-
paring two indicated groups 
 
 
Figure 4: Effect of compound 5i on memory 
retrival in step-through passive avoidance 
experiment: Results of the latencies to enter the 
dark compartment on the second day are 
presented. Results are shown as mean±SEM. In 
all groups n = 10. ns represents not significant, ** 
represents p < 0.01, and *** represents p < 0.001 
compared to the control group 
In silico toxicity evaluation 
The in silico toxicity risk assessment was 
performed by means of OPE and except com-
pound 5e which showed high risk of tumor-
igenic effect all of them can be considered as 
non-mutagenic, non-tumorigenic, non-irritant 
without any reproductive effects. 
Neurotoxicity evaluation 
According to Figure 5, compound 5i ex-
hibited no neurotoxicity effect in doses of 3.5, 
7 and 14 mg/kg. According to the BBB+ 
scores of compounds 5c, 5g and 5h, their in-
activity could be due to the low density in 
CNS. As shown in Table 2 compound 5b and 
5h are active in the MES model but their po-
tency is less than 5a, 5e and 5i. This may be 
due to their lower concentrations in the CNS, 
not less binding affinity to the receptor.  
 
 
Figure 5: Influence of the test compounds 5i (at 
3.5, 7 and 14 mg/kg) on motor coordination of ex-
perimental animals measured in the rotarod test 
revolving at 6 rpm. Results are shown as mean 
time spent on the rotating rod. 
 
CONCLUSION 
In summary, the new 4-thiazolidinone de-
rivatives as novel BZD agonists were synthe-
sized and their biological effects were inves-
tigated. Some of the novel synthesized com-
pounds showed antiepileptic effects in PTZ 
and MES tests. Compound 5i had the best 
anticonvulsant activity among the novel 4-
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thiazolidinone compounds and revealed 
considerable hypnotic effect. However, it did 
not change the antrograde memory and did 
not show neurotoxicity. Cosidering the fact 
that the most clinically used benzodiazepins 
have negative effect on memory, the novel 4-
thiazolidinone derivatives (specially 
compound 5i) can be used as leading 
compound and related derivatives can be 
designed and synthesized as novel ligands for 
benzodiazepine receptors which has 
minimum effect on memory.  
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